← Back to Search

Antiplatelet Agent

Standard blood pressure control plus aspirin 81 mg for Pre-eclampsia (ASAPP Trial)

Phase 2

Recruiting

Led By Megan C Oakes, MD MSCI

Research Sponsored by MemorialCare Health System

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Preeclampsia with severe features diagnosed during delivery admission, as defined by ACOG criteria.

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 weeks postpartum

Awards & highlights

ASAPP Trial Summary

This trial will evaluate whether taking aspirin after childbirth can help women with preeclampsia recover quickly and safely.

Who is the study for?

This trial is for women who have just given birth and were diagnosed with severe preeclampsia during delivery. They must be receiving care from the Long Beach Memorial Ob/Gyn or Maternal-Fetal Medicine clinic.Check my eligibility

What is being tested?

The study is testing if low-dose aspirin can help women recover faster from severe preeclampsia after childbirth by lowering a protein linked to high blood pressure in pregnancy.See study design

What are the potential side effects?

Low-dose aspirin may cause side effects such as stomach pain, heartburn, nausea, and an increased risk of bleeding. However, many people take it without any problems.

ASAPP Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I was diagnosed with severe preeclampsia during my delivery.

ASAPP Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 weeks postpartum

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 weeks postpartum

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 weeks postpartum for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Reduction in sFlt-1

Secondary outcome measures

Adherence

Anti-hypertensive therapy

Enrollment feasibility

+7 more

ASAPP Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Standard blood pressure control plus aspirin 81 mgExperimental Treatment1 Intervention

Standardized postpartum blood pressure control Aspirin 81 mg by mouth x 1 week post-delivery

Group II: Standard blood pressure controlActive Control1 Intervention

Standardized postpartum blood pressure control

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

MemorialCare Health SystemLead Sponsor

20 Previous Clinical Trials

2,469 Total Patients Enrolled

University of California, IrvineOTHER

544 Previous Clinical Trials

1,922,957 Total Patients Enrolled

Megan C Oakes, MD MSCIPrincipal InvestigatorMiller Children's and Women's Hospital, Long Beach/ MemorialCare Medical Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there vacancies for participants in this research trial?

"Data on clinicaltrials.gov suggests that this medical investigation is actively recruiting participants. This trial was initially posted on July 26th 2023 and most recently modified on December 15th 23."

Answered by AI

How many individuals are engaging in this experiment?

"That is accurate. According to clinicaltrials.gov, the medical trial that was first posted on July 26th 2023 is actively recruiting patients for participation. Currently 86 individuals need to be enrolled from one single site."

Answered by AI

How efficacious is the combination of Standard blood pressure control plus aspirin 81 mg for individuals?

"Based on our assessment, the level of safety for Standard blood pressure control plus aspirin 81 mg is judged to be a 2. This grade was assigned due the presence of data demonstrating its security but lacking any proof for efficacy."

Answered by AI

Recent research and studies

Obstetrics & GynecologyJournal

Acog

“Acog”. 2019. “Acog”. Obstetrics & Gynecology. Ovid Technologies (Wolters Kluwer Health). doi:10.1097/aog.0000000000003018.

Journal of HypertensionJournal

Hypertensive Disorders of Pregnancy and Postpartum Readmission in the United States

Mogos, Mulubrhan F., Jason L. Salemi, Kiara K. Spooner, Barbara L. McFarlin, and Hamisu H. Salihu. 2018. “Hypertensive Disorders of Pregnancy and Postpartum Readmission in the United States”. Journal of Hypertension. Ovid Technologies (Wolters Kluwer Health). doi:10.1097/hjh.0000000000001594.

clinicaltrials.govStudy

Aspirin for Postpartum Patients With Preeclampsia

Megan Oakes 2023. "Aspirin for Postpartum Patients With Preeclampsia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05924971.

All > Preeclampsia > Durlaza